[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 15, 1995

Interchangeability of Conjugated Haemophilus influenzae Type b Vaccines in Infants

Author Affiliations

From the Division of Infectious Diseases, Departments of Medicine and Pediatrics (Drs E. L. Anderson and Belshe), Saint Louis (Mo) University School of Medicine; the Departments of Preventive Medicine (Dr Decker), Medicine (Dr Decker), and Pediatrics (Dr Edwards), Vanderbilt University School of Medicine, Nashville, Tenn; the Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Tex (Dr Englund); the Department of Pediatrics, University of Rochester (NY) School of Medicine (Dr P. Anderson); and the Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Disease, Bethesda, Md (Dr Mclnnes). Drs Decker and Edwards have received honoraria from Lederle-Praxis Biologicals for speaking. Dr P. Anderson is a consultant to and stockholder in the manufacturer of one of the vaccines studied, but his role (the antibody assay) was done on coded specimens and he had no contact with the data decoding, data processing, or input on recommendations.

JAMA. 1995;273(11):849-853. doi:10.1001/jama.1995.03520350031024
Abstract

Objective.  —To evaluate the safety and immunogenicity of two Haemophilus influenzae type b (Hib) conjugate vaccines when administered in serial combination. These vaccines consisted of Hib capsular polysaccharide polyribosyl-ribitol phosphate (PRP) conjugated to the meningococcal outer membrane protein (OMP) complex (PRP-OMP) and H influenzae oligosaccharide conjugated to a mutant toxin (CRM197) isolated from Corynebacterium diphtheriae (HbOC).

Design.  —Randomized, double-blind, clinical trial evaluating five Hib vaccination regimens.

Setting.  —Vaccine Treatment and Evaluation Units and affiliated private pediatric practices at Saint Louis (Mo) University, Vanderbilt University, Nashville, Tenn, and Baylor College of Medicine, Houston, Tex.

Patients.  —A total of 497 healthy 2-month-old infants scheduled to receive routine immunization.

Intervention.  —Participants received either PRP-OMP or HbOC given as recommended by the manufacturer, PRP-OMP at 2 and 6 months, HbOC at 2 months, then PRP-OMP at 4 and 6 months, or PRP-OMP at 2 months and then HbOC at 4 and 6 months. Unconjugated PRP was given at 15 months to evaluate priming.

Results.  —Geometric mean antibody concentrations differed significantly among the groups following the second and third immunizations of the primary series and following booster immunization with unconjugated PRP. On each occasion, the groups receiving serial combinations of PRP-OMP and HbOC achieved mean antibody concentrations that equalled or exceeded those of the groups receiving a single product. Adverse reactions did not vary by group.

Conclusions.  —The studied sequential combinations of Hib vaccines were safe and at least as immunogenic as either vaccine alone.(JAMA. 1995;273:849-853)

×